I had read and also heard many times that,
“To prevent any side effect during any type of illness treatment, natural approach is the best one and always tried first.”
So, with this natural approach, here we will discuss “How true and effective it for Hemorrhoids!!”
There are some natural hemorrhoids cure that are quite effective and most people prefer them because these methods can treat hemorrhoids effectively and efficiently.
If used properly, then Natural Hemorrhoids Remedies can work very well, can prevent it from coming back by improving your vascular circulation and strengthening your veins.
They can treat the condition that is causing your hemorrhoids to keep reappearing. It can relieve the symptoms of hemorrhoids like itching, anal discomfort and burning.
At very first, we have to also keep control on our regular diet, just avoid foods that are causing your this disease to get worse, keeping track of diet that triggers this health condition to get worse.
(1) For temporary relief, apply an ice pack directly to the affected area.
(2) To soak this disease, a Sitz Bath is one of the best options also. The rectal area is soaked for 10 to 15 minutes 3 to 4 times a day to aid in relief and shrinkage of the hemorrhoids.
In today’s medical market, hemorrhoid medicines can only treat the symptoms instead of actually fixing what is causing the problem.
As Hemorrhoids natural remedies contains many of the best ingredients responsible for curing it, I will always stand as proof that this cure really works and works good.
Breast feeding for longer could help babies develop bigger brains, new research has revealed.
A three-year study of 128 mammal species, including humans, found that longer pregnancies and longer suckling times produce bigger brains in babies - possibly leading to a higher IQ.
The research, carried out by Durham University scientists, has been welcomed by
specialists and adds more weight to the argument that 'breast is best.'
Professor Robert Barton from the university's Department of Anthropology, said: 'Our findings cannot say whether formula milk for babies is adequate or just as good as a mother's milk in the development of a baby's brain, but it does raise questions that could be further investigated.
'The research we have done helps us to understand what the implications are of
evolutionary changes at different stages before and after birth.
'There is a strong relationship between specific issues in the way a mother invests in producing her offspring and a link between growth of the foetus and length of gestation.
'We now need to do more research into how growth before and after birth affects the anatomy of the brain.'
The scientists focused on brain and body size, maternal investment and life history variables in mammals, such as gorillas and whales. Published in the Proceedings of the National Academy of Sciences, the study
suggests that women who breastfeed their babies for up to three years following
nine-month pregnancies have a long period of dependency because it is required
to support the growth of 1,300 cubic centimetre (cc) brains.
But animals such as fallow deer, which have roughly the same body weight as humans, are pregnant for just seven months with a suckling period of up to six
months.
This results in 220cc brains - six times smaller than human brains.
Helen Robinson, public health specialist at NHS North of Tyne, said the analysis will support the World Health Organisation's advice of six months exclusive breastfeeding followed by suckling up to the age of two or beyond, supplemented with solid foods.
She added: 'This reinforces the need to encourage mothers to breastfeed in the first six months of a child's life and then for as long as possible after that.'
Mother-of-three Kerrie Graham, 27, from Newcastle, is breastfeeding her 10-month-old son Owen.
She said: 'It's really encouraging. It just goes to show how important breastfeeding is.'
Shares of Glenmark Pharmaceuticals rose nearly 2.5% on Thursday after the pharma giant announced discovery of a blood cancer drug GBR 401, which falls under biologic category of medicines. Athough discovery of the drug is a positive development, its impact on the company’s financials is a long term story, analysts said.
Biologics include a wide range of medicinal products such as vaccines, blood and blood components created by biological processes.
“It is a positive development for the company,” said Deepika Jain, senior analyst at KR Choksey. “We need to see when the company goes for out-licensing the product and file further trials of the drugs, which is currently under processing mode. The company has total of 10 molecules in pipeline out of which two are in-licensed and one-out-licensed. It's progressing well and the launch is expected in Q4FY12 and post FY15, respectively. All these discoveries hold future potentials.”
Good amount of funding is required in carrying out research to discover drugs. Hence, companies out-license the product to other companies, who also enjoy rights to the medicine. In turn, the former gets an upfront payment from the latter. KR Choksey has given a buy call on the stocks with a target price of Rs 379 while FirstCall set a target price of Rs 400. The stock is trading at a price to book value of 4.38x, which looks attractive. It has generated a positive return of over 14% in the last one month.
“Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR 401, an anti-CD19 monoclonal antibody. GBR 401 is developed completely in-house by Glenmark’s Biologics Research Centre located in Switzerland,” reads the press release sent by the company.
With an estimated 7,100 people getting infected with HIV every day and India home to 2.7 million HIV positive people, the government on Wednesday launched a new HIV vaccine design programme in the country. It was also announced that a new HIV Vaccine Laboratory will now come up in New Delhi.
Affordable medicines produced in India have played a major role in scaling up AIDS treatment to more than five million people across Asia, Africa and Latin America
M K Bhan, Secretary, Department of Biotechnology, said that autonomous institute Translational Health Sciences and Technology Institute (THSTI) and the International AIDS Vaccine Initiative (IAVI) have agreed to jointly establish, operate and fund an HIV vaccine design programme in the country.
The programme will primarily focus on one of the greatest scientific challenges of AIDS vaccine design and development: the elicitation of antibodies capable of neutralising a broad spectrum of circulating HIV variants — a problem that stems in large part from the almost unparalleled mutability of HIV. The programme will cost Rs 50 crore over five years.
Dr Rajat Goyal, director, country and regional programmes, IAVI, told The Indian Express that Rs 19.3 crore will be spent by IAVI on the programme. This is one of the key partnerships with the government to share scientific knowledge that will boost translational research, Goyal said.
THSTI director Dr Dinakar Salunke said there will be exchange of ideas in a mutually beneficial agreeement. A global search is underway to appoint scientists and directors. “There will be three principal investigators and 15 scientists,” Goyal added.
